SBIR Phase I: Combinatorial, controlled, and timed release of parylene encapsulated anti-cancer therapeutics

这个小企业创新研究（SBIR）第一阶段项目的重点是加强组合和定时释放的药物，用于癌症的局部治疗。目前，在手术切除乳腺癌（乳房肿瘤切除术）后，很少有局部消除肿瘤细胞的解决方案。对于以持续和安全的方式局部递送药物混合物的微创装置存在真实的未满足的需求。我们建议开发一种可植入的聚合物微膜装置，用于释放紫杉醇和吉西他滨，该装置无毒，舒适，患者可以接受。这项研究的更广泛影响是：-建立一个多学科的倡议，整合生物学，材料科学/工程和纳米技术的专业知识，以解决未满足的医疗需求。乳腺癌治疗的增强，加上下游治疗更广泛的其他疾病的机会，预计将改善全球患者的预后。通过新市场创造、产品开发和临床应用实现经济价值- Biotic Laboratories与洛杉矶和芝加哥地区的教育机构（高中和大学）有着密切的关系，并将实习活动作为其启动活动的一部分。总的来说，像Biotic这样的新兴创业公司既是经济增长的引擎，也是未来一代科学家和工程师的灵感来源。该奖项是根据2009年美国复苏和再投资法案（公法111-5）资助的。

This Small Business Innovation Research (SBIR) Phase I project focuses on enhancing combinatorial and timed release of drugs for the localized treatment of cancer. Currently there are few solutions for localized elimination of tumor cells following surgical removal of breast cancer (lumpectomy). There is a real unmet need for minimally invasive devices that locally deliver a cocktail of drugs in a sustained and safe fashion. We propose to develop an implantable polymer-based microfilm device for the release of Paclitaxel and Gemcitabine that is non-toxic, comfortable and cosmetically acceptable to the patient.The broader Impacts of this research are:- Establishment of a multidisciplinary initiative that integrates expertise in biology, materials science/engineering and nanotechnology to address an unmet medical need.- Enhancements in breast cancer treatment, coupled with downstream opportunities to treat a broader array of other diseases that are expected to improve patient outcomes globally.- Economic value through new market creation, product development and clinical applications- Biotic Laboratories has a strong relationship with educational institutions (high schools and universities) in the LA and Chicago area and has engaged intern activity as part of its start-up activities. In general, new entrepreneurial companies such as Biotic serve as both economic growth engines and inspiration to a future generation of scientists and engineers.This award is funded under the American Recovery and Reinvestment Act of 2009 (Public Law 111-5).